Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | METAP2 | P50579 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | KMO | O15229 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4461401 | 0.90 | ALOX5AP (0.31) | KDM1AALOX5AP | |
| SCHEMBL4470038 | 0.87 | HPGDS (0.39) | IDO1KDM4EALDH1A1LMNAGAA | |
| SCHEMBL4475112 | 0.86 | CHRNA7 (0.37) | KDM1AALOX5AP | |
| SCHEMBL4463819 | 0.86 | HSD11B1 (0.38) | NPY5RHSD11B1 | |
| SCHEMBL4460475 | 0.85 | FYN (0.41) | NPY5RHSD11B1 | |
| Bromide SCHEMBL4466117 | 0.85 | HSD11B1 (0.37) | NPY5RHSD11B1 | |
| SCHEMBL4460157 | 0.84 | KDM1A (0.43) | KDM1AIDO1KDM4EALDH1A1HPGD | |
| SCHEMBL4473786 | 0.82 | RAB9A (0.40) | IDO1ALDH1A1LMNASMN1; SMN2TDP1 | |
| SCHEMBL4483243 | 0.82 | CYP2A6 (0.41) | ALOX5APKDM4EALDH1A1ACHEHSD17B10 | |
| SCHEMBL5216772 | 0.81 | FYN (0.38) | KDM1AKDM4EALDH1A1HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7585974-B2 | Derivatives of 5-(pyridin-3-yl)-1-azabicyclo[3.2.1]octane, their preparation and their therapeutic application | SANOFI-AVENTIS (FR) | 2009-09-08 | — | — | US | claimed |
| US-20070185137-A1 | Derivatives of 5-(pyridin-3-yl)-1-azabicyclo[3.2.1]octane, their preparation and their therapeutic application | SANOFI-AVENTIS (FR) | 2007-08-09 | — | — | US | claimed |
| EP-1465893-B1 | DERIVATIVES OF 5-(PYRIDIN-3-YL)-1-AZABICYCLO (3.2.1) OCTANE, THE PREPARATION THEREOF AND THE APPLICATION OF SAME IN THERAPEUTICS | SANOFI AVENTIS (FR) | 2007-02-28 | — | — | EP | claimed |
| US-7585974-B2 | Derivatives of 5-(pyridin-3-yl)-1-azabicyclo[3.2.1]octane, their preparation and their therapeutic application | SANOFI-AVENTIS (FR) | 2009-09-08 | — | — | US | disclosed |
| US-20070185137-A1 | Derivatives of 5-(pyridin-3-yl)-1-azabicyclo[3.2.1]octane, their preparation and their therapeutic application | SANOFI-AVENTIS (FR) | 2007-08-09 | — | — | US | disclosed |
| US-7223750-B2 | Derivatives of 5-(pyridin-3-yl)-1-azabicyclo[3.2.1]octane, the preparation thereof and the application of same in therapeutics | SANOFI-AVENTIS (FR) | 2007-05-29 | — | — | US | disclosed |
| EP-1465893-B1 | DERIVATIVES OF 5-(PYRIDIN-3-YL)-1-AZABICYCLO (3.2.1) OCTANE, THE PREPARATION THEREOF AND THE APPLICATION OF SAME IN THERAPEUTICS | SANOFI AVENTIS (FR) | 2007-02-28 | — | — | EP | disclosed |
| US-20050020568-A1 | Derivatives of 5-(pyridin-3-yl)-1-azabicyclo[3.2.1] octane, the preparation thereof and the application of same in therapeutics | SANOFI (FR) | 2005-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185137-A1 | Derivatives of 5-(pyridin-3-yl)-1-azabicyclo[3.2.1]octane, their preparation and their therapeutic application | PAICS, CYC1, AADAC | KDM1A 1225/4885ALOX5AP 644/4885IDO1 44/4885 |
| US-20050020568-A1 | Derivatives of 5-(pyridin-3-yl)-1-azabicyclo[3.2.1] octane, the preparation thereof and the application of same in therapeutics | PAICS, NAT1, TPMT | KDM1A 866/4885ALOX5AP 878/4885IDO1 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.